On behalf of the ECOG-ACRIN Cancer Research Group
On July 21, President Donald Trump announced his latest set of sweeping tariffs on the pharmaceutical industry: a 200% levy on imported generic drugs by the year 2029.
Toward individualized breast cancer screening strategies—TMIST
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Principal investigator, TMIST
Professor in Residence of Radiology, Beth Israel Deaconess Medical Center
Professor in Residence of Radiology, Beth Israel Deaconess Medical Center
Henry Ledyard Goddard University Professor of Biostatistics, Chair, Department of Biostatistics, Brown University
Group co-chair, director, ECOG-ACRIN Cancer Research Group, Developmental Therapeutics Program, Abramson Cancer Center, professor of medicine, Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia
Group co-chair, ECOG-ACRIN Cancer Research Group; Eugene P. Pendergrass Professor of Radiology, The Perelman School of Medicine, University of Pennsylvania
Table of Contents
YOU MAY BE INTERESTED IN
In last week’s issue of The Cancer Letter, Raja Flores wrote a guest editorial explaining how he, with his expertise in thoracic surgery, took issue with a nuance in a recent Keytruda commercial.
My high school experience revolved around constantly worrying about my four younger siblings and mom amidst our normal condition—instability.
In November 2022, I was 43 years old, healthy, active, and the founding CEO of the publicly traded tech company GitLab.
Physician-scientists by day, a funk-loving musical troupe by night. You may have seen The CheckPoints—a 13 member cover band with a three-piece brass section and Jim Allison on harmonica—movin’, groovin’, and gettin’ down as a mainstay closing act at ASCO, AACR, or the Society for Immunotherapy of Cancer annual meetings.
One of the great pleasures of summer is having more time to read.
